Samer Abdul-Hay, Ph.D. - Publications

2009 University of Illinois at Chicago, Chicago, IL, United States 
Pharmacology, Neuroscience Biology, Pharmacy

18/23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Li H, Zhu H, Wallack M, Mwamburi M, Abdul-Hay SO, Leissring MA, Qiu WQ. Age and Its Association with Low Insulin and High Amyloid-β Peptides in Blood. Journal of Alzheimer's Disease : Jad. PMID 26444783 DOI: 10.3233/Jad-150428  0.72
2015 Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, et al. Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors. Acs Chemical Biology. PMID 26398879 DOI: 10.1021/Acschembio.5B00334  0.72
2014 Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, Siuda J, Wszolek ZK, Ross OA, Carrasquillo M, Dickson DW, et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Molecular Neurodegeneration. 9: 11. PMID 24607147 DOI: 10.1186/1750-1326-9-11  0.72
2014 Kurklinsky S, Abdul-Hay SO, McGuire MP, Howard EA, Knight J, Leissring MA. The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Mã©Tabolisme. 46: 73-4. PMID 23975847 DOI: 10.1055/S-0033-1353211  0.72
2013 Lincoln S, Allen M, Cox CL, Walker LP, Malphrus K, Qiu Y, Nguyen T, Rowley C, Kouri N, Crook J, Pankratz VS, Younkin S, Younkin L, Carrasquillo M, Zou F, ... Abdul-Hay SO, et al. LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD). Plos One. 8: e64164. PMID 23750206 DOI: 10.1371/Journal.Pone.0064164  0.72
2013 Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. Journal of Medicinal Chemistry. 56: 2246-55. PMID 23437776 DOI: 10.1021/Jm301280P  0.72
2012 Dunlap T, Piyankarage SC, Wijewickrama GT, Abdul-Hay S, Vanni M, Litosh V, Luo J, Thatcher GR. Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chemical Research in Toxicology. 25: 2725-36. PMID 23035985 DOI: 10.1021/Tx3003609  0.72
2012 Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA. Identification of BACE2 as an avid ß-amyloid-degrading protease. Molecular Neurodegeneration. 7: 46. PMID 22986058 DOI: 10.1186/1750-1326-7-46  0.72
2012 Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? Journal of Alzheimer's Disease : Jad. 29: 329-40. PMID 22232014 DOI: 10.3233/Jad-2011-111472  0.72
2011 Abdul-Hay S, Schiefer IT, Chandrasena RE, Li M, Abdelhamid R, Wang YT, Tavassoli E, Michalsen B, Asghodom RT, Luo J, Thatcher GR. NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor. Acs Medicinal Chemistry Letters. 2: 656-661. PMID 21927645 DOI: 10.1021/Ml2000033  0.72
2011 Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. Plos One. 6: e20818. PMID 21695259 DOI: 10.1371/Journal.Pone.0020818  0.72
2011 Schiefer IT, Abdul-Hay S, Wang H, Vanni M, Qin Z, Thatcher GR. Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. Journal of Medicinal Chemistry. 54: 2293-306. PMID 21405086 DOI: 10.1021/Jm101450P  0.72
2010 Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. Plos One. 5: e10504. PMID 20498699 DOI: 10.1371/Journal.Pone.0010504  0.72
2009 Abdul-Hay SO, Edirisinghe P, Thatcher GR. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. Journal of Neurochemistry. 111: 683-95. PMID 19702658 DOI: 10.1111/j.1471-4159.2009.06355.x  0.72
2009 Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR. NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. Journal of Neurochemistry. 111: 766-76. PMID 19702655 DOI: 10.1111/j.1471-4159.2009.06353.x  0.72
2009 Chirapu SR, Pachaiyappan B, Nural HF, Cheng X, Yuan H, Lankin DC, Abdul-Hay SO, Thatcher GR, Shen Y, Kozikowski AP, Petukhov PA. Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 264-74. PMID 19013792 DOI: 10.1016/J.Bmcl.2008.10.096  0.72
2008 Hagos GK, Abdul-Hay SO, Sohn J, Edirisinghe PD, Chandrasena RE, Wang Z, Li Q, Thatcher GR. Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention. Molecular Pharmacology. 74: 1381-91. PMID 18676677 DOI: 10.1124/Mol.108.046664  0.72
2008 Dunlap T, Abdul-Hay SO, Chandrasena RE, Hagos GK, Sinha V, Wang Z, Wang H, Thatcher GR. Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 19: 115-24. PMID 18485921 DOI: 10.1016/J.Niox.2008.04.013  0.72
Low-probability matches
2020 Suire CN, Abdul-Hay SO, Sahara T, Kang D, Brizuela MK, Saftig P, Dickson DW, Rosenberry TL, Leissring MA. Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40. Alzheimer's Research & Therapy. 12: 80. PMID 32631408 DOI: 10.1186/S13195-020-00649-8  0.01
2014 Medway CW, Abdul-Hay S, Mims T, Zou F, Ma L, Bisceglio G, Pankratz S, Sando S, Aasly J, Barcikowska M, Siuda J, Wszolek Z, Ross O, Carrasquillo MM, Dickson DW, et al. P1-055: MULTIPLE ABCA7 MISSENSE VARIANTS MINED FROM THE EXOME VARIANT SERVER SHOW INDEPENDENT ASSOCIATION WITH INCREASED OR DECREASED RISK OF LATE-ONSET ALZHEIMER'S DISEASE (LOAD) Alzheimer's & Dementia. 10: P323-P323. DOI: 10.1016/J.Jalz.2014.05.291  0.01
2011 Abdul-Hay S, Leissring M, Sahara T, McBride M, Kang D. O1-05-06: Functional cDNA screening identifies BACE-2 as a principal beta-amyloid degrading protease Alzheimer's & Dementia. 7: S105-S105. DOI: 10.1016/J.Jalz.2011.05.261  0.01
2010 DelleDonne A, Miles RJ, Dickson DW, Abdul-Hay SO, Ertekin-Taner N, Leissring MA. P1-292: Correlation between insulin-degrading enzyme levels and neuropathology in control versus Alzheimer brains with and without cerebral amyloid angiopathy Alzheimer's & Dementia. 6: S258-S258. DOI: 10.1016/J.Jalz.2010.05.844  0.01
2006 Thatcher GR, Bennett BM, Reynolds JN, Sutherland RM, Abdul-Hay S. P1-439: NO chimera drugs provide reversal of cognition deficits in animal models: GT 1061 an investigational new drug for Alzheimer's Alzheimer's & Dementia. 2: S226-S227. DOI: 10.1016/J.Jalz.2006.05.818  0.01
Hide low-probability matches.